Clinical Scorecard: Diabetic Retinal Disease Rates Narrow by Diabetes Type
At a Glance
| Category | Detail |
|---|---|
| Condition | Diabetic Retinal Disease (DRD), including vision-threatening forms (VTDR), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) |
| Key Mechanisms | Microvascular complications of diabetes affecting the retina, with prevalence and incidence influenced by diabetes type and disease management |
| Target Population | Patients with type 1 and type 2 diabetes in the United States |
| Care Setting | Outpatient and specialty care settings managing diabetic complications |
Key Highlights
- Prevalence of DRD increased from 2016 to 2021 in both type 1 and type 2 diabetes, with type 1 diabetes consistently showing higher rates.
- Incidence of overall DRD declined in type 1 diabetes and approached rates seen in type 2 diabetes by 2022, narrowing the incidence gap.
- Incidence of severe DRD subtypes (VTDR, DME, PDR) remained higher in type 1 diabetes, with some disparities widening, particularly for PDR.
Guideline-Based Recommendations
Diagnosis
- Use validated ICD codes for identifying diabetic retinal disease and its subtypes in administrative data.
- Recognize higher prevalence and incidence of DRD in type 1 diabetes patients compared to type 2 diabetes.
Management
- Implement advances in diabetes care to reduce incidence of DRD, especially in type 1 diabetes.
- Monitor and manage vision-threatening complications such as DME and PDR proactively.
Monitoring & Follow-up
- Regular retinal screening for all patients with diabetes, with heightened vigilance in type 1 diabetes due to higher risk.
- Track changes in DRD prevalence and incidence to adjust care strategies accordingly.
Risks
- Longer diabetes duration and complications increase DRD prevalence.
- Differences in disease subtype incidence suggest need for tailored monitoring and intervention.
Patient & Prescribing Data
3,682,484 patients with diabetes (101,579 type 1 diabetes; 3,580,905 type 2 diabetes) covered by commercial insurance and Medicare Advantage plans in the US
Declining incidence of DRD in type 1 diabetes may reflect improved diabetes management; however, persistent higher rates of severe DRD subtypes warrant continued targeted interventions.
Clinical Best Practices
- Maintain regular retinal screening schedules for both type 1 and type 2 diabetes patients.
- Focus on early detection and treatment of VTDR, DME, and PDR to prevent vision loss.
- Consider the narrowing incidence gap when planning resource allocation but recognize persistent higher burden in type 1 diabetes.
- Use administrative claims data cautiously, acknowledging limitations such as lack of clinical detail and potential impact of healthcare utilization changes.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
